H-Index
38
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
MSMbanner

AmJCaseRep
MedSciTechnol

eISSN: 2329-0358

Comparision of benefits of early, delayed, and no administration of G-CSF after autologous peripheral blood stem cell transplantation in lymphoma patients

Iwona Wyleżoł, Emilian Snarski, Mirosław Markiewicz, Sławomira Kyrcz-Krzemień, Wiesław-Wiktor Jędrzejczak, Jan Walewski

Ann Transplant 2013; 18:336-341

DOI: 10.12659/AOT.883965

Available online: 2013-07-02

Published: 2013-07-02


Background: Autologous peripheral blood stem cell transplantation (PBSCT) is commonly used in the treatment of lymphoma patients. G-CSF is widely used to boost white blood cell recovery. However, there are no clear data indicating which strategy of using G-CSF provides the most benefit. The aim of our study was to compare 3 strategies of G-CSF administration: from day +1, from day +5, and no administration.
Material and Methods: Data from 211 patients treated at 3 centers were gathered retrospectively. The patients in the 3 analyzed groups were not different in regard to type of disease, age, sex, and number of CD34+ cells received.
Results: The 3 strategies of G-CSF dosage had very similar results. G-CSF boosted the recovery of white blood cells and shortened the time of neutropenia. However, there were no differences in confirmed infections and the duration of hospitalization after transplantation.
Conclusions: Our results question the use of G-CSF in a post-PBSCT setting, as it does not provide significant benefits in reducing the number of infections or shortening the duration of hospitalization.

Keywords: GCSF, Lymphoma, autologous peripheral blood stem cell transplantation



Back